a-lap

4,9-Dihydroxy-alpha-lapachone has antitumor-promoting effects, it exhibits significant inhibitory activity against 12-O-tetradecanoylphorbol 13-acetate (TPA)-induced Epstein-Barr virus early antigen (EBV-EA) activation in Raji cells. 4,9-Dihydroxy-alpha-l

9-Hydroxy-alpha-lapachone can highly inhibit the growth of H. pylori, it exhibits potent inhibitory activity against H. pylori Cystathionine gamma-synthase, with IC(50) values of 4.64 microM. It may have anti-inflammatory activity, it exhibits potent inhi

9-Methoxy-alpha-lapachone, a potential EPHX2 (Epoxide Hydrolase 2) inhibitor, also inhibits NF-κB in HepG2 hepatoma cells.

1. Oroxylin A (Baicalein 6-methyl ether) has various anti-tumor effects including apoptosis, cell cycle arrest, drug-resistant reversion. 2. Oroxylin A possesses abilities of inhibiting the ATRA-induced IL-6 production via modulation of LAP LIP CHOP in leukemia cell lines, which could providing a therapeutic strategy for RAS. 3. Oroxylin A inhibits UCP2s triggers the MPTP opening, and promotes the apoptosis in CaCo-2 cells; uncoupling protein 2 plays a key role in mitochondrial apoptotic pathway. 4. Oroxylin A inhibits N1ICD translocating to the nucleus and binding to epithelial-mesenchymal transition-related transcription factor Snail, thus suppressing the invasion and migration of MCF-7 cells. 5. Oroxylin A improves the sensitivity of K562 ADM cells by increasing apoptosis in leukemic cells and decreasing the expression of CXCR4 and PI3K Akt NF-κB pathway, and probably served as a most promising agent for CML treatment.